Business

Government Revoked License Of 18 Pharma Companies, Read Below To Know Why

Following an inspection conducted under the supervision of the Drugs Controller General of India (DCGA), the government revoked licenses of 18 pharma companies. The decision came after it was revealed that the companies had been manufacturing spurious medicines across 20 states. On Tuesday, a surprise inspection of 76 pharmaceutical companies in 20 states and Union territories was conducted. The raid was carried out by a joint team of the state and central drug regulators.

An official source said, “Licenses of 18 pharma companies have been cancelled for manufacturing spurious and adulterated drugs and for violating GMP (good manufacturing practice). Besides, 26 firms have been given show-cause notices.”

Furthermore, the regulators identified 203 companies as a part of the special drive. Out of these companies, action has been taken in 70 firms from Himachal Pradesh, 45 in Uttarakhand and 23 in Madhya Pradesh. The raids were carried out as a result of concerns about the quality of drugs produced by Indian-based businesses.

Allegations on Indian-manufactured Drugs

 

Last month, more than 55,000 bottles of a generic gout treatment from the US market were recalled by the Gujarat-based pharmaceutical firm Zydus Lifesciences. The medication had not met the requirements for contaminants. Additionally,  in February, Global Pharma Healthcare, headquartered in Tamil Nadu, voluntarily recalled all of its eye drops in the US. This decision came after their eyedrops were allegedly linked to vision loss. Prior to this, three employees of a pharmaceutical company were detained in Noida. It was claimed that their cough medicine caused the deaths of 18 children in Uzbekistan last year. They were charged with producing and dispensing adulterated medication.

More such allegations have been made about Indian-manufactured drugs.

Meanwhile, the union health ministry is working on regulations for online pharmacies and tougher enforcement of those regulations. This is being done in response to growing concerns about data protection and dishonest business practices. Also, irrational drug sales. There is a possibility that the new regulations will be incorporated in the updated version of New Drugs, Medical Devises and Cosmetics Bills, 2023.

Malika Sahni

Recent Posts

PM Modi Congratulates Paris Paralympic Medalists Praveen Kumar And Hokato Hotozhe Sema In Telephonic Conversation

India's medal tally at the Paris Paralympics has risen to 27, comprising six golds, nine…

9 hours ago

Dr. Rajeshwar Singh Expresses Grief Over Transport Nagar Tragedy, Visits Injured, And Offers Financial Support

Dr. Rajeshwar Singh provided immediate financial assistance to the families of the injured, covering the…

9 hours ago

Talent Beyond Education: The Inspiring Journey of Padma Shri Awardee Premchand Sharma

Premchand saw potential in modernizing these methods. He introduced organic and high-tech techniques to grow…

11 hours ago

NGT Questions DDA’s Approval For Sewer Lines In Unauthorized Colonies On Yamuna Floodplain

The four colonies in question are New Aruna Nagar Colony (Majnu Ka Tila), Bhagat Singh…

11 hours ago

Gorakhpur Becomes Dream Destination For Education, Health And Investment: CM

Chief Minister Yogi Adityanath said that Gorakhpur is an important center in every respect with…

12 hours ago

High Court: Court Should Not Be Dragged Into The Bar Dispute, CJ Said

The rift between the office bearers of the High Court Bar Association has increased. People…

12 hours ago